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RESEARCH ARTICLE
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Abstract
Introduction: The retina and brain exhibit similar pathologies in patients diagnosed
with neurodegenerative diseases. The ability to access the retina through imaging techniques opens the possibility for non-invasive evaluation of Alzheimer’s disease (AD)
pathology. While retinal amyloid deposits are detected in individuals clinically diagnosed with AD, studies including preclinical individuals are lacking, limiting assessment
of the feasibility of retinal imaging as a biomarker for early-stage AD risk detection.
Methods: In this small cross-sectional study we compare retinal and cerebral amyloid
in clinically normal individuals who screened positive for high amyloid levels through
positron emission tomography (PET) from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial as well as a companion cohort of individuals who
exhibited low levels of amyloid PET in the Longitudinal Evaluation of Amyloid Risk and
Neurodegeneration (LEARN) study. We quantified the number of curcumin-positive
fluorescent retinal spots from a small subset of participants from both studies to determine retinal amyloid deposition at baseline.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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Results: The four participants from the A4 trial showed a greater number of retinal
spots compared to the four participants from the LEARN study. We observed a positive
correlation between retinal spots and brain amyloid, as measured by the standardized
uptake value ratio (SUVr).
Discussion: The results of this small pilot study support the use of retinal fundus imaging for detecting amyloid deposition that is correlated with brain amyloid PET SUVr. A
larger sample size will be necessary to fully ascertain the relationship between amyloid
PET and retinal amyloid both cross-sectionally and longitudinally.
KEYWORDS

Alzheimer’s disease, amyloid, NeuroVision, positron emission tomography, retina, retinopathy

1

INTRODUCTION

retinal imaging in clinically diagnosed AD individuals and have also
been shown to expand over time with disease progression.10 Amy-

Biomarker developments have focused on detecting abnormal cere-

loid can be contained in drusen, as seen in AMD retinas.11 These

bral amyloid deposition at the preclinical stage of Alzheimer’s disease

results imply that retinal deposits associated with amyloid may develop

(pAD). Identifying amyloid-positive asymptomatic subjects is critical

in AD patients. Curcumin, a fluorescent derivative of turmeric, binds

for efforts designed to intervene in pAD therapeutically.1 Even at this

to amyloid beta (Aβ) plaques in post mortem AD brain tissues.12 In

early preclinical stage, subtle cognitive decline is observed. Currently

vivo analysis from the Koronyo lab utilizing fundal imaging in persons

approved pAD biomarkers include amyloid-ligand positron emission

pretreated with curcumin supplementation has identified curcumin-

tomography (PET) and cerebrospinal fluid (CSF) amyloid levels; both

labeled deposits in the retinas of patients diagnosed with mild cognitive

approaches have been used to identify individuals with preclinical and

impairment (MCI) and mild to moderate AD.8,13 To date, no other lab

later-stage AD. The widespread use of such tests is limited currently

has replicated these observations, nor are there any other reports that

due to the expense and invasiveness of such testing. The development

have conducted retinal imaging studies to detect curcumin-labeled

of additional low-cost, non-invasive biomarkers to detect pAD patho-

retinal amyloid plaques.

logic changes is a priority in the field.

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease

Coined the “window to the brain,” the retina can develop

(A4) study is an active longitudinal trial including more than 1100

similar pathologic features to those seen in the brain in neurodegener-

asymptomatic individuals identified using amyloid PET criteria for ele-

ative disease states, as they both originate from the same embryonic

vated fibrillar amyloid in the brain. Individuals who “screen-failed” out

precursors.2 Standard clinical retinal assessments in patients with

of the A4 study due to low levels of amyloid PET could opt into the Lon-

neurodegenerative diseases, including AD, have shown alterations

gitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN)

contention.3

study, a longitudinal study running in parallel to the A4 trial that aims

Multiple AD retinal imaging studies with clinically diagnosed patients

to further characterize preclinical AD compared to normal aging.14

have found AD-mediated retinal changes, such as retinal neuronal

Participants in the LEARN study undergo the same clinical and cog-

layer thinning and vascular alterations, through optical coherence

nitive tests as their A4 counterparts. While the trial’s primary focus

tomography (OCT).4 Studies in preclinical populations also observed

is testing the efficacy of an anti-amyloid intervention in a preclinical

retinal neuronal layer reduction associated with other biomarkers

population, the trial also allows for novel biomarker development that

such as CSF amyloid and amyloid-PET.5,6 In summary, these studies

can be supported by correlation with established AD biomarkers.15 A

imply that the retina is susceptible to neurodegeneration in the AD

recent report from the A4 cohort indicated that elevated amyloid PET

state.

levels corresponded with lower test performance, family history, and

in the retinal tissue and vasculature, supporting this

In addition to retinal thinning, AD-associated pathology such as

apolipoprotein E (APOE) status.14

extracellular amyloid plaques have been reported in post mortem AD

Upon completing the double-blind portion, participants in the A4

retinal tissue through histological analysis.7,8 As the retina can be mon-

trial can choose to continue treatment in an open-label extension

itored in a non-invasive manner, a few studies have sought to detect

phase, paralleled by extended observational follow-up in the LEARN

retinal pathology related to amyloid plaques in real-time through

cohort. The results from this extension will provide enhanced data on

retinal fundal imaging. Retinal inclusion bodies were observed in a

longer-term longitudinal outcomes and will further allow an extended

population with a family history of AD through BluePeak autofluo-

period for discovery concerning both established and novel biomarkers

rescence, with inclusion body surface area increasing as a function of

for pAD.

amyloid-PET

levels.9

Hard drusen, often associated with age-related

The retinal imaging addendum to the A4 trial has three specific

macular degeneration (AMD), were identified through ultra-widefield

aims: (1) to characterize retinal amyloid in subjects with preclinical
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AD prior to administration of the experimental treatment provided
in the primary A4 study protocol, (2) to characterize the longitudi-

RESEARCH IN CONTEXT

nal trajectory of retinal amyloid in subjects with preclinical AD, and
(3) to correlate retinal amyloid with brain amyloid and cognitive
change. Approximately 50 A4 study participants across five A4 study
sites elected to participate in the retinal imaging component, allowing for a thorough retinal assessment of pAD. Previous studies have
used retinal fundus imaging to detect retinal amyloid in mildly cognitively impaired and clinically diagnosed AD patients, which are populations with demonstrated cognitive decline.8,13,16 However, few studies
have reported using this type of imaging to detect amyloid in the retina
before the onset of behavioral and cognitive symptoms. The overall
study is actively recruiting more participants from the A4 and LEARN
trial to the retinal addendum, but the number of participants in this current study was limited as the retinal imaging addendum was approved

1. Systematic review: Studies assaying retinal amyloid
through fundus imaging with fluorescent probes have
yielded promising results in clinically diagnosed dementia patients. However, to date no studies have used
retinal fundus imaging to assess the progression of
dementia. The Anti-Amyloid Treatment in Asymptomatic
Alzheimer’s Disease (A4) trial included a pilot retinal
scanning protocol intended to investigate the diagnostic feasibility of retinal imaging for Alzheimer’s disease
(AD). In this pilot cross-sectional study, we analyzed
retinal scans taken from four amyloid positron emission tomography (PET)-positive individuals and four amyloid PET-negative individuals for curcumin-labeled retinal

when the main trial had started.
This small pilot study aims to (1) determine whether retinal amyloid expression can be detected in preclinical individuals and asymptomatic individuals and (2) ascertain the difference in retinal amyloid expression across individuals with elevated amyloid brain PET.
Retinal scans from four A4 and four LEARN participants with similar
demographic features were quantified regarding curcumin-laden retinal amyloid expression, and these results were compared to quantitative amyloid brain PET standardized uptake value ratio (SUVr) measurements. These scans were taken before randomization to quantify
retinal amyloid at baseline without the influence of solanezumab.

deposits.
2. Interpretation: We observed more retinal amyloid
curcumin-labeled fluorescently positive deposits in four
individuals with elevated amyloid PET levels compared
to four individuals with low levels of amyloid PET. While a
larger sample is necessary to establish the value of retinal
amyloid for predicting amyloid PET or other methods
of identifying the pathology of AD, our data suggest
that amyloid is prevalent in the retinas of preclinical AD
individuals.
3. Future directions: Continuous retinal sampling of the
A4 amyloid PET-positive population and Longitudinal

2

Evaluation of Amyloid Risk and Neurodegeneration

METHODS

(LEARN) amyloid PET-negative population is necessary to

2.1

fully assess the potential diagnostic applications of this

Study design

approach to retinal imaging. Future studies focusing on
Subjects volunteering for the retinal amyloid imaging addendum were
screened into the parent A4 or LEARN study based on amyloid PET
results as previously described.15 In this pilot study, participants with

the pathophysiology of the retinas of AD patients would
inform the biological conditions required to form retinal
amyloid deposits.

retinal scans prior to randomization were analyzed. Because the retinal imaging addendum was a late addition to the A4 trial, the number
of participants in the current study was limited to four. Participants
were excluded from the study if they had: any condition that might be

a liquid nutritional supplement such as Ensure and taken on an empty

harmed by retinal amyloid imaging; an allergy to curcumin; or any other

stomach. Although Aβ plaques exhibit blue light autofluorescence,17,18

condition that, in the opinion of the principal investigator, warranted

curcumin binding to amyloid in vivo may increase the fluorescent sig-

exclusion. All participants in this study signed informed consent before

nature, serving as a contrast reagent to highlight suspected retinal

participating in the addendum. Eligible participants underwent a base-

amyloid deposits. Previous studies have validated the use of Longvida

line retinal amyloid scan after the fourth screening visit and before

curcumin as an in vivo tracer for retinal amyloid detection.8,19 On the

randomization. The previous published 10-day curcumin loading pro-

day of the retinal scanning session, individuals received one drop of

tocol was modified to a 2-day protocol. Curcumin concentrations in the

1% tropicamide and 2.5% phenylephrine in each eye and then sat in

blood and retinal deposit fluorescent intensity increased after 2 days of

a darkened room until their pupils were dilated greater than 3.5 mm.

curcumin administration; therefore, the prescribed curcumin dose was

Corrective lenses, such as spectacles or contact lenses, were removed

concentrations.8

during the examination to prevent reflection artifacts from obscur-

Participants were instructed to consume 20 g (one packet) of Longvida

ing the retinal scan. The RETIA 2 imaging system (EyeCare) is a Food

curcumin twice daily (40 g/day) for 2 days (a total of 80 g) before the

and Drug Administration (FDA)-approved confocal scanning ophthal-

site visit and to avoid acidic food and liquid 1 hour before and after each

moscope equipped to detect the fluorescence characteristics of cur-

dose to maximize absorption. The Longvida curcumin was mixed into

cumin in addition to naturally occurring fluorophores in the retina by

adjusted to reach the previously reported curcumin
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exciting with blue light at 450 nm and collecting emitted light above

3

RESULTS

500 nm.20 Both eyes were scanned from each participant at the visit
except in the case of cataracts impeding proper visualization of the

Retinal scans from four participants in the A4 trial taken prior to ran-

retina. A minimum of six autofluorescent images was taken at three

domization, along with four retinal scans from participants with similar

points in the central and superior regions of the retina, for a total of

demographics in the LEARN retinal imaging trial were analyzed. Par-

18 autofluorescent images per region. An image was taken every 5 sec-

ticipant information, amyloid PET SUVr, retinal spot counts, and APOE

onds to account for LED cycle time and a minimum of 90 seconds spent

status are presented in Table 1. Right eye spot counts were missing for

imaging each region. The superior regions are more likely to contain

one amyloid-positive individual due to cataracts. In addition, the right

amyloid deposits, as demonstrated in the histologic evidence.6 The A4

eye scans of one amyloid-negative individual failed the quality check

retinal imaging study is a subset of the parent A4 study; therefore, amy-

and were excluded from the analysis. Therefore, a total of 14 eyes were

loid PET SUVr levels and thresholds were determined as previously

processed, 7 from each cohort. Equal numbers of female (n = 4) and

described.14

male (n = 4) participants from the two cohorts were included in this
pilot study. The minimum age was 65, the maximum age was 74, and

2.2

the median age was 69 years. Two amyloid-positive individuals had an

Sites

APOE genotype ε3/ε4, and the remaining two had APOE ε3/ε3 and APOE
The A4 retinal imaging protocol was conducted across five A4 sites.

ε2/ε3. All amyloid-negative individuals had an APOE ε3/ε3 genotype.

Participants in this particular pilot study were pooled from the Univer-

Individuals with SUVr values above 1.15 were designated amyloid-

sity of Kentucky and Butler Hospital Memory and Aging sites.

positive (median: 1.21, minimum: 1.16, maximum: 1.34), as previously
described.14,22 In contrast, the amyloid-negative individuals’ SUVr val-

2.3

ues were below 1.15 (minimum: 0.90, maximum: 1.13, median: 1.01).

Retinal image analysis

To evaluate the association between brain amyloid levels and reti-

Retinal image analysis was performed as previously described.13,16
Briefly, the set of retinal images was processed through an automated proprietary image analysis software system (NeuroVision Imaging, Inc.). The software algorithmically determined the quality of each
set of retinal images, taking into account focus, contrast, variations in
illumination, eye motion, obstruction, and fixation. The eight highestscoring images from each set were further processed for quantification
of retinal spots, referred to as spot count, as described previously.13,16
A design of experiments exercise aiming to maximize measurement
repeatability recognized that eight images were optimal using an 18image study.

nal amyloid, we plotted retinal spot count against the SUVr values
from all eight individuals. Total retinal spots varied between eyes in
the same individual (Figure 1A). Both sides exhibited an increase in the
number of spots that coincided with higher SUVr levels. The range of
spot counts between eyes within a subject increased in individuals with
SUVr values over 1.20, suggesting unequal amyloid expression in each
retina. However, it is unclear if retinal amyloid accumulation favored a
particular side (Figure 1B). Bivariate analysis indicated a modest positive association between SUVr values and total retinal spots (Pearson’s r: 0.65, 95% CI: –0.093, 0.930; Figure 1C). Amyloid PET-negative
individuals had fewer total spots (difference in means: –538, 95% CI: –
979 to –97) compared to amyloid PET-positive individuals (Figure 1D).
Furthermore, the range of the number of spots was greater for amy-

2.4

Statistical analysis

loid PET-positive individuals compared to amyloid PET-negative individuals. To account for the variance between samples, we implemented

Total spot count, amyloid PET SUVr, and age were summarized as medi-

a LME21 model in which we included subject-specific random inter-

ans and ranges and organized by amyloid positivity status.14

The asso-

cepts. In addition to a fixed effect for amyloid PET SUVr, we also con-

ciation between spot counts and amyloid PET SUVr was visualized with

sidered a fixed-effect covariate for side (left vs. right eye). The AIC

scatter plots, with separate linear regression trend lines for the left

preferred the model without the effect for side (AIC 189.6 vs. 191.6),

and right eyes and for the bilateral average of spot counts. The associa-

which estimated the effect of amyloid PET SUVr to be 1611.5 spots per

tion between bilateral spot counts and amyloid PET SUVr was assessed

SUVr (95% CI –248.2 to 3471.1). The results from the LME are consis-

using Pearson’s correlation coefficient and its 95% confidence interval

tent with the ordinary least squares trend line and Pearson correlation

(CI). Spot counts were plotted by amyloid PET positivity status, and the

shown in Figure 1C derived from bilateral averages (1608.1 spots per

difference in means between amyloid groups was provided along with

SUVr, 95% CI –246.2 to 3462.3).

the 95% CI. When spot counts from one eye were missing, the bilateral average from the other eye was used as the observed value. We
also modeled bilateral spot counts using a linear mixed-effect (LME)

4

DISCUSSION

model in which we included participant-specific random intercepts.21
We considered two models: the first with a fixed effect for amyloid PET

We provide evidence in this feasibility study that implies that reti-

SUVr and the second with fixed effects for amyloid PET SUVr and side

nal amyloid can be detected in the preclinical stage of AD and

(left vs. right eye). We use the Akaike information criterion (AIC) to

that such retinal pathology is associated with amyloid PET SUVr

select the preferred model.

(Figure 1). All four individuals from the A4 trial exhibited more
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TA B L E 1

Demographics of eight individuals from the A4 and LEARN retinal imaging cohorts
Amyloid- (N = 4)

Amyloid+ (N = 4)

Total (N = 8)

1.01 (0.90, 1.13)

1.21 (1.16, 1.34)

1.15 (0.90, 1.34)

Female

2 (50.0%)

2 (50.0%)

4 (50.0%)

Male

2 (50.0%)

2 (50.0%)

4 (50.0%)

69 (65, 74)

69 (65, 72)

69 (65, 74)

ε2/ε3

0 (0.0%)

1 (25.0%)

1 (12.5%)

ε3/ε3

4 (100.0%)

1 (25.0%)

5 (62.5%)

ε3/ε4

0 (0.0%)

2 (50.0%)

2 (25.0%)

245.0 (178.5, 301.5)

750.2 (473.0, 1149.0)

387.3 (178.5, 1149.0)

Amyloid PET SUVr
Median (range)
Sex

Age at consent
Median (range)
APOE

Spot count
Median (range)

Spot count values are the bilateral average of both eyes when data from both eyes are available.
Abbreviations: A4, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease; APOE, apolipoprotein E; LEARN, Longitudinal Evaluation of Amyloid Risk
and Neurodegeneration; PET, positron emission tomography; SUVr, standardized uptake value ratio.

curcumin-positive spots in the retina compared to individuals from the

nal study using a similar retinal fundus imaging system reported a

LEARN trial, suggesting that a discernable difference exists between

region-specific increase of retinal spots in individuals diagnosed with

the two groups (Table 1). Previous studies into curcumin-labeled amy-

MCI and AD, suggesting regional amyloid deposition may indicate dis-

loid in the retina have studied clinically diagnosed individuals that

ease progression.13 The software used in this study is proprietary

exhibit cognitive deficits as early as

MCI,8,10

while retinal studies of

and may not be readily accessible, which may limit the feasibility of

preclinical cohorts have observed retinal inclusion bodies.9 Our pilot

this study. However, a retinal imaging system’s costs may be rela-

study of the A4 retinal imaging prospective study extends the applica-

tively small compared to the costs and infrastructure of PET imaging.

tion of curcumin labeling, demonstrating that elevated levels of reti-

Our curcumin loading protocol also differs from the Koronyo et al.

nal curcumin-positive spots can be detected in amyloid PET-positive

study as we decreased the number of days required to take curcumin

asymptomatic individuals. We aim to provide data in our feasibility

and compensated by increasing the amount of curcumin administered.

study that can be used to design robust and well-powered retinal imag-

While curcumin amounts were based on the 2017 Koronyo et al.

ing studies.

study, a blood pharmacokinetic study would further confirm previous

OCT is the most common imaging modality used to study the

observations. Future studies should also include such analysis in their

AD patient retinas due to its widespread clinical use and availabil-

protocol. However, in vivo retinal curcumin labeling has confirmed

ity, allowing a quantitative measure of retinal layer characteristics

amyloid deposits in the retina but is not essential for amyloid detec-

in real time. Although the degeneration of specific retinal layers has

tion. Blue-light autofluorescence imaging without a contrast reagent

been suggested to reflect cortical atrophy in a single study,23 other

was sufficient in detecting retinal amyloid deposits.9 Contrast reagent-

studies have observed no significant association with AD-mediated

free quantification of retinal amyloid is currently under development,

neurodegeneration.24

which may provide a more accessible method for retinal detection of

Fundus imaging, while lacking axial resolution

and potentially requiring contrast reagents, as in the present study,
provides topological information about potential amyloid plaque accumulation that may be associated with brain amyloid accumulation.

pAD.
This study’s limitations include small sample sizes and the fact that
scans were obtained from different retinal imaging devices (albeit

Curcumin binds to amyloid in vivo and has been used as a con-

the same system) at different test sites. Due to the potential effects

trast reagent to identify amyloid deposits in the retina of individuals

of solanezumab study treatment on amyloid PET SUVr and retinal

diagnosed with MCI as well as mild to moderate AD.8,13 While the

spot counts, only participants with retinal scans prior to randomiza-

total spots quantified in the Koronyo et al. study are lower than what

tion were included in this study. Other factors such as cataracts and

is presented in our studies, this may be due to the use of different

image quality further reduced the total number of eyes analyzed. While

retinal imaging systems and quantification

methods.8

The algorithm-

some of these variables are unavoidable, these issues must be con-

mediated analysis in the current study allows for unbiased, auto-

sidered in future studies when recruiting for a retinal imaging study.

mated quantification of the retinal scans, reducing the likelihood of

Advance screening of participants for potential cataracts before imag-

regional selection biases, inter-site and scan variability, and allowing

ing would ensure that data are retrieved from both eyes. However, we

for a standardized retinal amyloid quantification process. A recent reti-

believe that retinal trends are apparent and demonstrate a discernable
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F I G U R E 1 Comparison of retinal amyloid to brain amyloid. A, Total retinal spot counts from each eye over amyloid positron emission
tomography (PET) standardized uptake value ratio (SUVr; left eye: n = 8, right eye: n = 6). B, Plot of total retinal spots from both eyes of each
individual (n = 8). C, Distribution of bilateral average retinal spots from all eyes (n = 8) with Pearson’s correlation (r) and 95% confidence interval
(CI). D, Distribution of bilateral average spots grouped by amyloid PET SUVr level (amyloid+: n = 4, amyloid-: n = 4) and difference in means (δ)
with 95% CI

difference that is worth reporting. More importantly, these data fur-

yield exciting results, as a recent curcumin retinal study observed

ther align with previous retinal fundus imaging trials in AD patients. As

an inverse correlation between retinal spots and hippocampal

the A4/LEARN retinal imaging trial is ongoing, we can expect to collect

volume.13

longitudinal data that will allow for a more comprehensive analysis of

We implement both bivariate and mixed model approaches in ana-

retinal amyloid changes over time. Larger sample sizes will allow us to

lyzing our data to demonstrate that even though our sample is small, we

look into the effects of sex and age on AD-associated retinal changes.

arrived at the same results regardless of the method chosen. Averag-

A larger sample size allows for additional analysis to factor in effects

ing values, especially in small data sets, may hide variations within the

from other AD cofactors such as family history, APOE status, and cog-

dataset. We achieved smaller confidence interval widths by using LME

nitive ability.

in our small dataset. While our conclusions remain the same regardless

We observed a modest correlation between brain PET SUVr and
retinal spot count, suggesting a pathologically relevant relationship

of the analysis in our study, future studies with larger datasets should
undoubtedly consider implementing LME in their data analysis.

between the brain and the retina. While a recent study suggests a

In summary, we detected elevated curcumin fluorescence levels sug-

relationship between the primary visual cortex and the inner plexiform

gesting that amyloid is present in the retinas of asymptomatic amyloid

layer of the retina,25 multiple regions of the neocortex were measured

PET-positive individuals. The retinal imaging section of the A4 trial is

to calculate SUVr in this current study. Future retinal imaging study

actively recruiting individuals, which will provide data to characterize

designs may consider measuring other brain regions associated with

retinal amyloid pathogenesis. Determining the onset, spread, and mor-

the retina, such as the lateral geniculate and primary visual cortex.

phology of AD will guide the use of retinal imaging as a biomarker for

Measurements of other layered regions such as the hippocampus may

preclinical diagnosis.
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